Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

Key facts

Sponsor

National Cancer Institute (NCI)

Principal Investigator

Mark R Litzow

ECOG-ACRIN Cancer Research Group

Intervention

Allogeneic Hematopoietic Stem Cell Transplantation(procedure)

Enrollment

488 enrolled

Eligibility

30-70 years · All sexes

Timeline

2014 – 2026

Study locations (30)

• University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
• Anchorage Associates in Radiation Medicine, Anchorage, Alaska, United States
• Anchorage Radiation Therapy Center, Anchorage, Alaska, United States
• Alaska Breast Care and Surgery LLC, Anchorage, Alaska, United States
• Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States
• Alaska Regional Hospital, Anchorage, Alaska, United States
• Alaska Women's Cancer Care, Anchorage, Alaska, United States
• Anchorage Oncology Centre, Anchorage, Alaska, United States
• Katmai Oncology Group, Anchorage, Alaska, United States
• Providence Alaska Medical Center, Anchorage, Alaska, United States
• Fairbanks Memorial Hospital, Fairbanks, Alaska, United States
• Kingman Regional Medical Center, Kingman, Arizona, United States
• Banner University Medical Center - Tucson, Tucson, Arizona, United States
• University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
• Mercy Hospital Fort Smith, Fort Smith, Arkansas, United States
• +15 more locations on ClinicalTrials.gov

Collaborators

Canadian Cancer Trials Group

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Acute lymphoblastic leukemia

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT05621291
  A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...
  National Cancer Institute (NCI)
• RECRUITINGPHASE2NCT07328503
  CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
  National Cancer Institute (NCI)
• RECRUITINGPHASE2NCT06738368
  Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia
  University of Washington
• ENROLLING BY INVITATIONNCT07511959
  Autologous Exosomes From Platelet-rich Plasma as a Modern Tool of Regenerative Dentistry
  Wroclaw Medical University
• RECRUITINGNANCT07191119
  Transcutaneous Auricular Vagus Nerve Stimulation for Insomnia in Survivors of Childhood Acute Lymphoblastic Leukemia
  St. Jude Children's Research Hospital
• RECRUITINGPHASE2NCT07275762
  Y-4 to Treat the Postherpetic Neuralgia
  Neurodawn Pharmaceutical Co., Ltd.
• RECRUITINGNANCT07177183
  Low Serum Creatinine as a Predictor of Prolonged Mechanical Ventilation and Weaning Failure
  University Hospital Ostrava
• ENROLLING BY INVITATIONNCT07515430
  The Association Between Gut Microbiome Composition Signature and Cancer-related Symptoms in Children With Acute Lymphoblastic Leukemia
  Sun Yat-sen University

See all trials for Acute lymphoblastic leukemia →